MADRIGAL PHARMACEUTICALS, INC. Long-Term Debt, Maturity, Remainder of Fiscal Year
MADRIGAL PHARMACEUTICALS, INC. (MDGL) had Long-Term Debt, Maturity, Remainder of Fiscal Year of $15.17 million as of 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Notes › Commitment and Contingencies
us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear · last filed 2026-07-30
- 2026-06-30: Long-Term Debt, Maturity, Remainder of Fiscal Year $15.17M.
- 2026-03-31: Long-Term Debt, Maturity, Remainder of Fiscal Year $22.59M.
- 2025-09-30: Long-Term Debt, Maturity, Remainder of Fiscal Year $7.83M.
- 2025-06-30: Long-Term Debt, Maturity, Remainder of Fiscal Year $5.82M.
| Period end | Long-Term Debt, Maturity, Remainder of Fiscal Year |
|---|---|
| 2026-06-30 | $15.17M 10-Q · filed 2026-07-30 |
| 2026-03-31 | $22.59M 10-Q · filed 2026-05-06 |
| 2025-09-30 | $7.83M 10-Q · filed 2025-11-04 |
| 2025-06-30 | $5.82M 10-Q · filed 2025-08-05 |
| 2025-03-31 | $8.74M 10-Q · filed 2025-05-01 |
| 2024-09-30 | $3.07M 10-Q · filed 2024-10-31 |
| 2024-06-30 | $6.40M 10-Q · filed 2024-08-07 |
| 2024-03-31 | $9.62M 10-Q · filed 2024-05-07 |
| 2023-09-30 | $3.10M 10-Q · filed 2023-11-06 |
| 2023-06-30 | $5.37M 10-Q · filed 2023-08-08 |
| 2023-03-31 | $6.77M 10-Q · filed 2023-05-09 |
| 2022-09-30 | $1.27M 10-Q · filed 2022-11-03 |
| 2022-06-30 | $2.20M 10-Q · filed 2022-08-04 |
| 2013-09-30 | $233.00K 10-Q · filed 2013-11-04 |
| 2013-06-30 | $452.00K 10-Q · filed 2013-08-01 |
| 2013-03-31 | $618.00K 10-Q · filed 2013-04-30 |
| 2012-09-30 | $1.97M 10-Q · filed 2012-11-06 |
| 2012-06-30 | $3.93M 10-Q · filed 2012-08-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |